Mary Lynne Hedley
CIK 1340823 · President & COO · last filed 2026-06-24
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$4.44M
Companies
8
Total Filings
118
Lifetime Open-Market Net
-$1.06M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Centessa Pharmaceuticals plc (CNTA) Delisted | Director | — | $40.50 | — | $0 | 5 | 2026-06-24 |
| VEEV | Director | 7,152 | $230.47 | $1.65M | -$146.4K | 42 | 2026-06-22 |
| LLY | Director | 2,350 | $1185.71 | $2.79M | $0 | 44 | 2025-12-16 |
| Tempest Therapeutics, Inc. (MLND) Delisted | Director | — | $15.90 | — | $0 | 4 | 2020-06-23 |
| TESARO, Inc. (TSRO) Delisted | President & COO | 0 | — | — | -$909.0K | 10 | 2019-01-22 |
| bluebird bio, Inc. (BLUE) Delisted | Director | 185 | $4.97 | $919 | $0 | 2 | 2018-06-22 |
| Receptos, Inc. (RCPT) Delisted | Director | 0 | — | — | $0 | 2 | 2015-08-27 |
| MGI PHARMA INC (MOGN) Delisted | Exec VP & Chief Scientific Off | 18,250 | — | — | $0 | 5 | 2008-01-25 |
Recent Filings · Page 6 of 12
118 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-07-13 | VEEV | Sell (S) | −230 | -$47.8K | EDGAR |
| 2023-07-12 | VEEV | Notice (144) | −230 | -$47.7K | EDGAR |
| 2023-06-23 | Centessa Pharmaceuticals plc (CNTA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-06-23 | VEEV | Grant (A) | — | $0 | EDGAR |
| 2023-06-21 | LLY | Grant (A) | +22 | $9.9K | EDGAR |
| 2023-06-05 | VEEV | Exer (M) | +326 | $0 | EDGAR |
| 2023-05-16 | LLY | Grant (A) | +23 | $10.0K | EDGAR |
| 2023-04-19 | LLY | Grant (A) | +27 | $10.1K | EDGAR |
| 2023-03-22 | LLY | Grant (A) | +30 | $10.0K | EDGAR |
| 2023-03-03 | VEEV | Exer (M) | +327 | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.